IP Library Granted Patent US 11,130,979
Granted Patent B2
US 11,130,979 · App. 16/624,616 · Granted Sep 28, 2021

Protein expression strains

Inventors: Christopher John Arthur Finnis (Nottingham, GB); Per Kristoffer Nordeide (Copenhagen, DK); Jennifer Mary McLaughlan (Nottingham, GB)
Assignee: Albumedix Ltd
C12P21/00C12N9/93C12N15/81C12Y603/02002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,130,979
App. No.
16/624,616
Granted
Sep 28, 2021
Kind
B2
Abstract

The invention provides an improved host strain for production of desired protein.

Claims (65)

1. A fungal host cell having:

a. a reduced level of Gsh1 protein, and/or

b. a reduced activity level and/or expression level of Gsh1 protein, and/or

c. a reduced level of GSH1 gene, and/or

d. a reduced level of expression of GSH1 gene and

a nucleotide sequence encoding a heterologous protein wherein the heterologous protein is a serum protein or an albumin protein, and

wherein the reduced level is relative to the level of a reference fungal host cell identical to the host cell with the exception of the GSH1 gene and/or Gsh1 protein, wherein the GSH1 gene of the reference encodes wild-type Gsh1 protein and/or the Gsh1 protein of the reference is wild-type Gsh1.

2. The fungal host cell of claim 1 , wherein the reduced level is relative to the level of a reference fungal host cell in which the Gsh1 protein is SEQ ID NO: 2 and/or the GSH1 gene is SEQ ID NO: 1.

3. The fungal host of claim 1 having:

a. a reduced level of Not4 protein, and/or

b. a reduced activity level and/or expression level of Not4 protein, and/or

c. a reduced level of NOT4 gene, and/or

d. a reduced level of expression of NOT4 gene

wherein the reduced level is relative to the level of a reference fungal host cell identical to the host cell with the exception of the NOT4 gene and/or Not4 protein, wherein the NOT4 gene of the reference encodes wild-type Not4 protein and/or the Not4 protein of the reference is wild-type Not4.

4. The fungal host cell of claim 3 , wherein the reduced level is relative to the level of a reference fungal host cell in which the Not4 protein is SEQ ID NO: 6 and/or the NOT4 gene is SEQ ID NO: 5.

5. The fungal host cell according to claim 1 wherein the fungal host is a yeast or a filamentous fungus.

6. The fungal host cell according to claim 1 , wherein the albumin protein is human albumin.

7. The fungal host cell according to claim 1 in which the Gsh1 protein comprises a mutation at a position corresponding to a position selected from 47, 48, 49, 50, 51, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 409, 451, 452, 453, 454 and 455 of SEQ ID NO: 2.

8. The fungal host cell according to claim 7 in which the mutation at a position corresponding to position 125 of SEQ ID NO: 2 is a substitution to A, C, D, E, F, G, H, I, L, M, N, P, Q, S, T, V, W or Y.

9. The fungal host cell according to claim 1 in which the Gsh1 protein is SEQ ID NO: 4 and/or the GSH 1 gene is SEQ ID NO: 3.

10. The fungal host cell according to claim 1 in which the host cell lacks a GSH1 gene or Gsh1 protein.

11. The fungal host cell according to claim 3 in which the Not4 protein comprises a mutation at position corresponding to a position selected from 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469 or 470 of SEQ ID NO: 6.

12. The fungal host cell according to claim 11 in which the mutation at a position corresponding to position 429 of SEQ ID NO: 6 is a substitution to A, C, D, E, G, H, I, K, L, M, N, P, Q, R, S, T, V, W or Y.

13. The fungal host cell according to claim 3 in which the Not4 protein is SEQ ID NO: 8 and/or the NOT4 gene is SEQ ID NO: 7.

14. The fungal host cell according to claim 1 in which the fungal host is a Saccharomyces.

15. A method for increasing the yield of a heterologous protein comprising culturing a fungal host cell to produce the heterologous protein, wherein the fungal host cell has

1. a reduced level of Gsh1 protein, and/or

2. a reduced level of activity of Gsh1 protein, and/or

3. a reduced level of GSH1 gene, and/or

4. a reduced level of expression (preferably reduced) of GSH1 gene, and

a nucleotide sequence encoding the heterologous protein, wherein the heterologous protein is a serum protein or an albumin protein, and

wherein the reduced level is relative to the level of a reference fungal host cell identical to the fungal host cell with the exception of the GSH1 gene and/or Gsh1 protein, wherein the GSH1 gene of the reference fungal host cell encodes wild-type Gsh1 protein and/or the Gsh1 protein of the reference fungal host cell is wild-type Gsh1.

16. The method according to claim 15 in which the yield of the heterologous protein is at least 2% higher than the yield from the reference fungal host cell.

17. The method according to claim 15 , in which the fungal host cell has:

1. a reduced Not4 protein, and/or

2. a reduced level of activity of Not4 protein, and/or

3. a reduced NOT4 gene, and/or

4. a reduced level of expression of NOT4 gene wherein the reduced level is relative to the level of a reference fungal host cell identical to the host cell with the exception of the NOT4 gene and/or Not4 protein, wherein the NOT4 gene of the reference encodes wild-type Not4 protein and/or the Not4 protein of the reference is wild-type Not4.

18. The method according to claim 17 in which the yield of the heterologous protein is at least 2% higher than the yield from the reference fungal host cell.

19. The method according to claim 15 in which the albumin protein in human albumin.

20. The method according to claim 15 in which the host cell is cultured at a scale of at least 5 L.

21. The fungal host cell of claim 1 , wherein the albumin protein is at least 98% identical to human serum albumin (HSA) having the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 12.

22. The fungal host cell according to claim 7 comprising a mutation at a position corresponding to a position selected from R125, D49, H409 and P453.

23. The fungal host cell according to claim 8 , wherein the mutation at the position corresponding to position 125 of SEQ ID NO: 2 is a substitution to G.

24. The fungal host cell according to claim 8 , wherein the mutation at the position corresponding to position 125 of SEQ ID NO: 2 is a substitution to C.

25. The fungal host cell according to claim 8 , wherein the mutation at the position corresponding to position 125 of SEQ ID NO: 2 is a substitution to D.

26. The fungal host cell according to claim 8 , wherein the mutation at the position corresponding to position 125 of SEQ ID NO: 2 is a substitution to E.

27. The fungal host cell according to claim 12 , wherein the mutation at the position corresponding to position 429 of SEQ ID NO: 6 is a substitution to I.

28. The fungal host cell according to claim 12 , wherein the mutation at the position corresponding to position 429 of SEQ ID NO: 6 is a substitution to L.

29. The fungal host cell according to claim 12 , wherein the mutation at the position corresponding to position 429 of SEQ ID NO: 6 is a substitution to V.

30. The fungal host cell according to claim 12 , wherein the mutation at the position corresponding to position 429 of SEQ ID NO: 6 is a substitution to G.

31. The fungal host cell according to claim 12 , wherein the mutation at the position corresponding to position 429 of SEQ ID NO: 6 is a substitution to A.

32. The fungal host cell according to claim 14 , wherein the fungal host is Saccharomyces cerevisiae.

33. The method according to claim 15 , further comprising recovering the heterologous protein.

34. The method according to claim 15 , further comprising purifying the heterologous protein.

35. The method according to claim 15 , further comprising formulating the heterologous protein with a therapeutically acceptable carrier or diluent thereby to produce a therapeutic product suitable for administration to a human or an animal.

36. The method according to claim 15 , further comprising providing the heterologous protein in unit dosage form.

37. The method according to claim 15 in which the fungal host is a yeast or a filamentous fungus.

38. The method according to claim 15 in which the yeast is Saccharomyces cerevisiae.

39. The fungal host cell of claim 15 , wherein the reference fungal host cell has the GSH1 gene of SEQ ID NO: 1 and/or the Gsh1 protein of SEQ ID NO: 2.

40. The method according to claim 17 , wherein the reference fungal host cell has the Not 4 protein of SEQ ID NO: 6 and/or the NOT4 gene of SEQ ID NO: 5.

41. The method according to claim 17 , wherein the reference fungal host cell has

a. the GSH1 gene of SEQ ID NO: 1 and/or the Gsh1 protein of SEQ ID NO: 2, and

b. the NOT4 gene of SEQ ID NO: 5 and/or the Not4 protein of SEQ ID NO: 6.

42. The method according to claim 41 in which the yield of the desired protein is at least 2% higher than the yield from a reference fungal host cell.

Assignments (2)
CHANGE OF NAME Recorded Mar 11, 2025
From: ALBUMEDIX LTD
To: SARTORIUS ALBUMEDIX LIMITED
Reel/Frame 070468/0573 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2020
From: FINNIS, CHRISTOPHER JOHN ARTHUR; NORDEIDE, PER KRISTOFFER; MCLAUGHLAN, JENNIFER MARY
To: ALBUMEDIX LTD.
Reel/Frame 052691/0077 →
Priority Claims (1)
EP 17176932 · Jun 20, 2017 · regional
Continuity (1)
Related Publication 20200123584A1 · Apr 23, 2020
Cited By (1)
US 12,371,457